[Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].
Gaucher disease -due to its low frequency- is considered an orphan disease. In 1991 the International Gaucher Registry was created and in 1992 the first patients from Latin America were enrolled. In 2008 the Latin American Group for Gaucher Disease was initiated. Its main objectives are to promote regional consensus, to stimulate the enrollment of patients into the International Gaucher Registry and the enhancement of knowledge on this disease, and to achieve better care and quality of life of patients in our Region. Until April 2010, 5828 patients have been enrolled all around the world, 911 (15.6%) from Latin America. This is the first comprehensive report of the disease in the Region. In our population there is a predominance of females, the most common clinical form is the type I (95%) and the age at diagnosis is before 20 years in 68% of patients. The most frequent clinical manifestations at diagnosis are splenomegaly (96%) and anemia (49%). Eighty percent of patients had radiographic findings of bone involvement. In our Region, the vast majority of patients (89%) had received enzyme replacement therapy with imiglucerase; with a long follow-up (up to 10 years) they have achieved the therapeutic goals, showing the great effectiveness of therapy. While the percentage of patients with therapy is high, discontinuations are common. The main deficiencies in our Region are: the lack of visceral volumetric evaluations and densitometries as well as molecular analysis for some patients. The main problem is the under-diagnosis of patients.
Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina. drgdrelichman@yahoo.com.ar
Guillermo
G
Drelichman
Adriana
A
Linares
Jacobo
J
Villalobos
Juan Francisco
JF
Cabello
Marcelo
M
Kerstenetzky
Regina M
RM
Kohan
Ana María
AM
Martins
D000740:Anemia / Q000209:etiology; D056947:Enzyme Replacement Therapy; D005260:Female; D005776:Gaucher Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D014943:Global Health / Q000706:statistics & numerical data; D005962:Glucosylceramidase / Q000627:therapeutic use; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D008297:Male; D035583:Rare Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D017678:Sex Distribution; D013163:Splenomegaly / Q000209:etiology
D005962:Glucosylceramidase; C090568:imiglucerase